ArticleFrontiers in neurology2025
Predicting hemorrhage expansion in patients with hypertensive intracerebral hemorrhage: the HE-VSD-A2TP score.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk stratification and prognostic outcomes in intracerebral hemorrhage among patients with chronic kidney disease: a population-oriented meta-analysis.Frontiers in medicine · 2026Pooled it
- Risk and Timing of Intracerebral Hemorrhage Expansion Among Patients Treated with Antithrombotic Agents.Neurocritical care · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hematoma expansion (HE) in hypertensive intracerebral hemorrhage (HICH) is significantly associated with patient mortality. Early identification of HE would be planning for appropriate and aggressive management for improving outcome and containing HE. Existing HE prediction models show variable accuracy across settings. To address this limitation, we developed and validate a new predictive model to enhance the accuracy of HE in patients with HICH. Methods: We conducted a retrospective cohort study using data from two centers. The primary outcome was the occurrence of HE within 24 h of symptom onset, defined as an increase in hematoma volume ≥33% or ≥12.5 mL on follow-up imaging. Logistic regression was used to identify independent predictors of HE, and the HE-VSD-A Results: Five hundred and sixty seven patients in the derivation cohort and 378 patients in the validation cohort. The HE-VSD-A Conclusion: The HE-VSD-A2TP score was validated to be an effective tool for identifying patients at risk of HE in patients with HICH. It was a valuable tool for guiding clinical management strategies and potentially improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.